Please assess the completion status of the following clinical trial:

Trial Title: Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has given written informed consent before any trial-related activities are carried out~* Male or female, greater than or equal to (\>=)18 years of age at the time of informed consent, inpatient or outpatient~* Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIB NSCLC with pleural effusion or stage IV~* Presence of at least 1 uni-dimensionally measurable index lesion, whereby index lesions must not lie in a previously irradiated area~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at inclusion in the trial~* White blood count\>= 3 \* 10\^9 per liter (/L) with neutrophils \>= 1.5 \* 10\^9 /L , platelet count \>=100 \* 10\^9 /L , and hemoglobin \>= 5.6 millimole per liter (mmol/L) (9 gram per deciliter \[g/dL\])~* Total bilirubin less than or equal to (=\<)1.5 \* upper limit of normal (ULN) range~* Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) =\< 5 \* ULN~* Glomerular filtration rate (GFR) \>=60 milliliter per minute (mL/min). The creatinine clearance (CrCl) estimated based on the Cockroft-Gault formula is used as a surrogate for the GFR~* Effective contraception that is, barrier method (condoms, diaphragm), oral, injectable or implant birth control, for both male and female subjects during the whole trial period and for at least 6 months after the end of trial treatment, if the risk of conception exists~* Recovered from relevant toxicities prior to inclusion in the trial~Exclusion Criteria:~* Previous exposure to Epidermal Growth Factor Receptor (EGFR)-targeting therapy~* Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is allowed if it was finished 6 months prior to start of trial treatment~* Major surgery within 30 days prior to inclusion in the trial~* Prior chest irradiation within 90 days prior to inclusion in the trial (palliative radiation of bone lesions is allowed)~* Participation in another clinical trial or treatment with any investigational agent(s) within 30 days prior to inclusion in the trial~* Concurrent chronic systemic immune therapy, chemotherapy for disease other than cancer, or hormone therapy for the treatment of cancer not indicated in the trial protocol~* Documented or symptomatic brain metastasis~* Pre-existing ascites Grade \>= 2 and/or pericardial effusion Grade \>= 2~* Superior vena cava syndrome contra-indicating hydration~* Previous malignancy in the last 5 years except basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~* Active infection (infection requiring intravenous antibiotics), including active tuberculosis, known and declared human immunodeficiency virus (HIV)~* Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder despite treatment~* Known hypersensitivity reaction to any of the components of trial treatments~* Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Grade \>= 2 and/or ototoxicity Grade \>= 2, except if due to trauma or mechanical impairment due to tumor mass~* History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder~* Medical or psychological condition that would not permit the subject to complete the trial or sign informed consent~* Legal incapacity or limited legal capacity~* Known drug abuse~* Pregnancy (absence to be confirmed by serum beta-human chorionic gonadotropin \[beta-HCG test\]) or lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab 250 mg/m^2 q1w + Platinum-based Doublet Chemotherapy (Type: ACTIVE_COMPARATOR): None
- Cetuximab 500 mg/m^2 every 2 weeks (Type: ACTIVE_COMPARATOR): None
- Cetuximab 250 mg/m^2 weekly (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).